Initiate late-stage trial for GEM103 in patients with GA
The company cancelled or abandoned the commitment
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 15 Nov 2021
- Due
- 31 Mar 2022
- Withdrawn
- 1 Jan 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expect to initiate late-stage trial for GEM103 in patients with GA in 1Q’22”
What we found
Evidence strength A What the grades mean
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2022.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- late-stage trial for GEM103
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “Not met”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the recorded outcome.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Disc Medicine, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IRON-002103 · Corrections policy